G2G Bio

Innovating sustained-release treatments for dementia, diabetes, and obesity.

founder

Heeyong Lee

founded

2017

field

BIO∙Healthcare

"Beyond just providing capital, Laplace Partners actively connects us with key partners and investors globally, driving real growth as true collaborators in our long-term success journey."


Related Posts

G2G Bio Passes Technical Evaluation for IPO

Subscribe

By subscribing, you agree to our Privacy Policy.

KR

© 2025 Laplace Partners

Subscribe

By subscribing, you agree to our Privacy Policy.

KR

© 2025 Laplace Partners

Subscribe

By subscribing, you agree to our Privacy Policy.

KR

© 2025 Laplace Partners